Key facts
- CoreMap’s last known valuation is $67.3M (Feb 2022).
- It has raised $44.1M across 3 recorded rounds; the latest was Early Stage VC ($35.5M) in Jun 2026.
- Notable investors include US National Science Foundation, Northpoint Capital Group, DRIVEN Accelerator Hub, Dudley Fund, Hula — 12 tracked in total.
- CoreMap has filed 2 Form Ds with the SEC since 2022, most recently Jul 2025 ($6.8M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for CoreMap
Funding rounds
3 roundsAbout CoreMap
Developer of a diagnostic technology designed to enable curative treatment options. The company's technology uses a micro-electrode design that can map sequentially and overcome the two main obstacles of atrial fibrillation which have poor spatial resolution and inadequate sample density, enabling medical practitioners to improve outcomes for patients.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2016
- Employees
- 40
- Website
- coremapmedical.com/
- Ownership
- Privately Held (backing)
CoreMap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CoreMap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CoreMap in its N-PORT filings yet. We sweep new filings monthly.